Ameloblastic carcinoma is a rare type of ameloblastoma that has received little mention in the literature. While a number of cases have been published over many years, no institution has been able to produce a substantial case series. Ameloblastic carcinoma originates in the embryonic tooth components. It is believed to be an aggressive tumor that can metastasize; once metastasis occurs, the prognosis tends to be poor. Ameloblastic carcinoma is primarily a surgical condition that is best treated with resection; there has been little indication that other modalities are helpful. We present the case of a 40-year-old woman who was found to have a mandibular lesion by a dentist. After surgical resection, the tumor was found to be an ameloblastic carcinoma. The patient recovered without complication, and she was recurrence-free 18 months postoperatively. We also briefly review the available literature on the natural history of and management options for this rare tumor.
Introduction
Ameloblastoma is a common benign odontogenic tumor of the oral cavity that arises from the epithelial components of the embryonic tooth. 1 It occurs in the mandible in 80% of cases and in the maxilla in the other 20%. 2 It can occur in any age group, but it is most common in the third to fifth decades of life. 2 Ameloblastoma is subdivided into four types-solid/ multicystic (the most common worldwide), unicystic, extraosseous/peripheral, and desmoplastic-based on its radiologic appearance. While ameloblastomas are benign, they can be locally aggressive and destructive; they can even lead to death by invading important ad-jacent structures. The solid/multicystic type is believed to be the most aggressive of the four types in terms of invasiveness and recurrence. 1, 3 The two most dangerous sites of involvement are the ascending ramus of the mandible and the posterior maxilla due to their proximity to vital structures of the orbit, pterygomaxillary fossa, and cranium. 4 Ameloblastoma is also differentiated from malignant ameloblastoma and ameloblastic carcinoma, according to the latest WHO classification of head and neck odontogenic tumors. 1 • Malignant ameloblastoma is a histologically benign lesion that metastasizes and maintains the same benign architecture in the metastatic lesions.
• Ameloblastic carcinoma is a histologically malignant lesion that may or may not metastasize. 1 The initial presentation of these two types of lesion is similar, so it can be difficult to differentiate them. The most common presenting sign is a painless swelling of the affected area; other signs include an unhealed dental extraction site, draining sinuses, a superficial ulceration, and neural involvement. 5, 6 In this article, we discuss a case of ameloblastic carcinoma that was originally believed to be a benign ameloblastoma.
Case report
A healthy, nonsmoking 40-year-old woman presented with an expansile bony lesion on the anterior aspect of the right mandible. She had had the lesion for 9 months, and she had been seen by a dentist, who treated her conservatively in view of her concurrent pregnancy. Subsequent to the delivery of her child, she noticed that the size of the lesion had increased and that her medial and lateral incisors had become loose.
Clinical examination revealed a 3.5-cm solid lesion with cystic areas centered on the anterior aspect of the Volume 93, Number 9 www.entjournal.com  E35 A rAre cAse of AmeloblAstic cArcinomA right hemimandible. The mass had expanded the bone on both the lingual and buccal aspects, and there was significant soft-tissue involvement. The patient also exhibited paresthesia in the area of the right mental nerve, which suggested involvement of the same. No cervical adenopathy was noted. At this point, we suspected that the tumor was a benign ameloblastoma. However, findings on further workup, which included a biopsy, were suggestive of an ameloblastic carcinoma.
The patient underwent a segmental mandibulectomy, and the tumor was completely resected. Reconstruction was performed with a fibula free flap. Histopathology of the excised specimen confirmed the diagnosis of an ameloblastic carcinoma (figures 1-4). At 18 months postoperatively, the patient remained disease-free.
Discussion
Ameloblastic carcinoma is rare tumor, representing only 1.1 to 4% of all odontogenic tumors. 7 At the time of this writing, fewer than 70 cases had been reported in the literature. 8 The key difference between ameloblastoma and ameloblastic carcinoma is the innate malignant potential of the latter. There is a poor understanding of the biology and behavior of ameloblastic carcinoma due to the scarcity of reported cases. However, based on limited clinical experience collated from series published over many years, it appears that it is an aggres-sive tumor. It is not known whether tumor suppressor genes or oncogenes are important factors in determining its behavior, but a number of studies of molecular biology and DNA sequencing have not produced any strong evidence to document the mechanism of cancer progression. 3, 6, 9 Ameloblastic carcinoma can present as a unicystic or multilocular lesion associated with bone resorption and tooth mobility. While the tumor cells are similar to those of benign ameloblastoma, they are nonetheless highly atypical and they lack the distinctive architecture of the benign form, which predicts their clinically apparent aggressive course. 10 Ameloblastic carcinoma can arise de novo (most cases) as well as ex ameloblastoma, 9 particularly subsequent to multiple resections and/or radiotherapy. 11 The diagnosis of ameloblastic carcinoma is usually based on the history, clinical examination, radiologic features, and histopathologic interpretation of biopsy specimens. It is interesting that more than one type of ameloblastoma or ameloblastic carcinoma can be present within a given lesion, 11 thus leaving the possibility of a sampling error.
The treatment of choice is an adequate surgical resection with a 1-to 2-cm margin. If local lymphadenopathy is present, neck dissection should be added to the surgical protocol. 10, 12 Although ameloblastoma in general is believed to be radioresistant, 13 radiotherapy has been used successfully in a number of cases, both solely and in combination with surgery. 14 Chemotherapy alone has not found a place in the treatment of ameloblastoma or ameloblastic carcinoma. However, in the setting of metastatic disease, a small benefit has been shown with a cisplatin/doxorubicin/cyclophosphamide regimen. 15 Recurrences and metastases are common, and a high proportion of patients die of this disease. 12, 16 The most common sites of metastatic ameloblastic carcinoma are the lungs, bones, pleura, brain, and liver. 17 Close and prolonged follow-up of all patients with ameloblastic carcinoma is required. While the reported median survival after treatment of a primary tumor is 11 to 14 years, the median survival after detection of a metastasis is only 3 months to 5 years. 10, 18 
